Ottobock SE & Co. KGaA, the listed global MedTech company, has appointed Dr. Katarzyna Mazur-Hofsaess to its Management Board effective 22 June 2026. She succeeds Stefan Heidenreich, whose regular five-year term on the Management Board has come to an end.
“With Dr. Katarzyna Mazur-Hofsaess, we are gaining a proven expert in international medical technology and healthcare. Her experience in global companies and her medical background will be a valuable addition to our Board,” says Professor Hans Georg Nader, Chairman of the Management Board of Ottobock SE & Co. KGaA.
Dr. Mazur-Hofsaess has many years of international experience in medical technology and healthcare. From 2018 to 2025, she was a member of the Management Board of Fresenius Medical Care and CEO of the company MedTech segment Care Enablement. Prior to that, she was responsible for the EMEA region at Zimmer Biomet, the US-based specialist in joint replacement solutions. Earlier in her career, she held positions at Abbott Diagnostics and Roche Polska. She is also currently active as an independent, non-executive Director at Smith & Nephew.
A physician by training, Dr. Mazur-Hofsaess studied and earned her doctorate at the Medical University of Gdansk. She also completed management studies at the Warsaw School of Economics and the University of Minnesota. She began her professional career at the University Clinical Centre in Gdansk.
Stefan Heidenreich is stepping down from the Management Board following the scheduled end of his regular five-year term of office. As Deputy Chairman of the Management Board, he played a key role in shaping the company’s strategic development. Ottobock expressly thanks him for his work and the expertise he contributed to the company’s development into a listed company.
This appointment is significant for Ottobock as it brings in a leader with deep expertise in medical technology and healthcare, which could drive innovation in prosthetics, neuro-orthotics, and exoskeletons. Dr. Mazur-Hofsaess’s experience at global companies like Fresenius Medical Care and Zimmer Biomet positions her to contribute to Ottobock’s strategic goals. The leadership change also marks a transition after Heidenreich’s term, which was crucial for the company’s evolution into a publicly listed entity. For more details, visit the original release on NewMediaWire.
